Stock code: 300759.SZ

Stock code: 3759.HK

2025

First Quarterly Results

April 2025Disclaimer

The documents opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co. Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in

presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to

the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law and the

recipients into whose possession this Document comes should inform themselves about and observe such restrictions. By accessing this Document you are agreeing (i) that you have read and agree to comply with the

contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell or any solicitation of any offer to subscribe for or

purchase any securities in any jurisdiction in which the making of such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise

be in compliance with the laws and regulations of such jurisdiction and nothing contained herein shall form the basis of any investment decision contract or commitment whatsoever. This Document contains no

information or material which may result in it being deemed (1) to be an advertisement invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and

Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being

able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice.The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933 as amended (the “U.S. Securities Act”) or under the laws of any state of the United States. This Document

does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed directly or indirectly in or into the United

States (including its territories and possessions any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an

exemption from or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any

copy hereof may be directly or indirectly taken or transmitted into or distributed in the United States Canada Australia Japan PRC Hong Kong or any other jurisdiction which prohibits the same except in compliance

with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws. Upon request the recipient will promptly return this Document and any

other written information made available in the presentation without retaining any copies.This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation warranty or undertaking express or implied is given

and so far as is permitted by law no responsibility or liability is accepted by any person (for the avoidance of doubt including but not limited to the Company and its affiliates controlling persons directors officers

partners employees agents representatives or advisers of any of the foregoing) with respect to the accuracy reliability correctness fairness or completeness of this Document or its contents. The information

communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will" "expects" “intends” “plans to” and "anticipates" and words of

similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the

Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ materially from these forward-looking statements. In particular but without limitation no representation

or warranty is given as to the achievement or reasonableness of and no reliance should be placed on any assumptions projections targets estimates forecasts or any forward-looking statements contained in this

Document. Each of the Company and its affiliates controlling persons directors officers partners employees agents representatives or advisers of any of the foregoing assumes no obligation to update or otherwise

revise these forward-looking statements for new information events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates controlling persons directors officers partners

employees agents representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of or reliance upon the information contained herein by you or any person

to whom the information herein is disclosed.In furnishing this Document the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may

become apparent.

21Q2025 Financial Performance

RMB mm 1Q2024 1Q2024 YoY

Revenue 2671 3099 16.0%

Net Profit 231 306 32.5%

Non-IFRSs Net Profit 339 349 3.1%

Net Operating Cash Flow 746 853 14.4%

? The launch of the biologics CDMO facility in Ningbo in 2Q2024 and higher labor costs vs.

1Q2024 (mainly driven by workforce expansion in 2H2024) caused a temporary divergence

between the growth rates of revenue and Non-IFRSs net profit

? Building on the industry’s initial recovery and rapid growth of the new POs in 1Q2024 in

1Q2025 the Company’s new POs achieved 10%+ YoY growth

? Maintain 2025 guidance of 10~15% revenue growth

Data are rounded to the nearest million. 1Q2024 and 1Q2025 financials are unaudited 31Q2025 Revenue Compositions

Segments Revenue Composition Global Customers Revenue Composition

Biologics & CGT ROW 2%

Services 3% NA Revenue Grew 16.8%

Clinical Development China

Services 14% EU Revenue Grew 26.6% 15%

CN Revenue Grew 13.1%

Laboratory North Europe

Services 60% America 18%

65%

Small Molecule

CDMO Services

22%

China/Overseas Entities Revenue Composition Diversified Customer Base Revenue Composition

New Customers

1%

China Entities Overseas TOP 20 Pharmas TOP 20

Subsidiaries

Revenue Grew 15.7% Revenue Grew 29.1% Pharmas

12%15%

Overseas Subsidiaries Other Customers

Revenue Grew 18.3% Revenue Grew 14.0%

China Entities Other Repeat

88% Customers 84%

41Q2025 Laboratory Services

RMB mm 1Q2024 1Q2025 YoY

Revenue 1605 1857 15.7%

Gross Margin 44.1% 45.5% 1.4pct

? Supported by a moderate industry recovery both laboratory chemistry and bioscience

services delivered strong revenue growth YoY

? Driven by economies of scale the GPM improved slightly both QoQ vs.4Q2024 & YoY vs.

1Q2024

? New POs increased by 10%+ YoY

Data are rounded to the nearest million. 1Q2024 and 1Q2025 financials are unaudited 51Q2025 CMC (Small Molecule CDMO) Services

RMB mm 1Q2024 1Q2025 YoY

Revenue 582 693 19.1%

Gross Margin 27.9% 30.4% 2.5pct

? New POs increased by 10%+ despite a high base effect from the major POs signed in

1Q2024

? Expect to achieve QoQ revenue growth in 2Q2025 with more project deliveries

Data are rounded to the nearest million. 1Q2024 and 1Q2025 financials are unaudited 61Q2025 Clinical Development Services

RMB mm 1Q2024 1Q2025 YoY

Revenue 392 447 14.2%

Gross Margin 9.3% 11.8% 2.5pct

? China clinical development services achieved strong revenue growth YoY; overseas clinical

development services delivered steady revenue growth YoY

? Despite intensive competitions in China market GPM improved YoY driven by operating

leverage

Data are rounded to the nearest million. 1Q2024 and 1Q2025 financials are unaudited 71Q2025 Biologics & CGT Services

RMB mm 1Q2024 1Q2025 YoY

Revenue 91 99 7.9%

Gross Margin -38.6% -68.9% -30.3pct

? Biologics laboratory & CDMO services achieved strong revenue growth YoY

? Gene therapy CDMO services delivered steady revenue growth YoY while the revenue of

CGT testing services slightly declined YoY

? The emerging segment is still in the investment stage. The launch of the biologics CDMO

facility in Ningbo in 2Q2024 resulted in increased operating costs and depreciation during the

Reporting Period

Data are rounded to the nearest million. 1Q2024 and 1Q2025 financials are unaudited 81Q2025 Expenses for the Period

Selling and Distribution Expenses as % of Total Revenue Administrative Expenses as % of Total Revenue (1)

13.4%14.2%12.7%12.8%12.9%

2.2%2.2%2.1%2.1%2.2%

2022 2023 2024 1Q2024 1Q2025 2022 2023 2024 1Q2024 1Q2025

R&D Costs as % of Total Revenue Net Finance Costs as % of Total Revenue (2)

3.9%3.8%3.9%

3.5%0.9%0.8%1.0%

2.9%

0.1%0.1%

2022 2023 2024 1Q2024 1Q2025

2022 2023 2024 1Q2024 1Q2025

1. Excluding share-based compensation expenses recognized in administrative expenses 9

2. Net finance costs including interest expenses on bank borrowings and lease liabilities interest income and bank wealth management products related gains or lossesExpect to Continue to Achieve Positive Free Cash Flow in 2025

RMB mm

29502865

2754

2577

2143

2041

853

746

499556

2022 2023 2024 1Q2024 1Q2025

Net Operating Cash Flow CAPEX

101Q2025 Non-IFRSs Adjusted Net Profit Attributable to Owners of the Company

RMB mm 1Q2024 1Q2025

Net Profit 231 306

Add:

Share-based Compensation Expenses 33 16

Convertible Bonds Related Losses / (Gains) (7) -

Foreign Exchange Related (Gains) / Losses 25 2

Realized and Unrealized (Gains) / Losses From Equity

1326

Investments

Amortization of Intangible Assets from Acquisitions - 0

One-off Loss Made by Pharmaron Shanghai Co.

440

Ltd. due to the Business Close

Non-IFRSs Net Profit 339 349

Data are rounded to the nearest million. 1Q2024 and 1Q2025 financials are unaudited 112025 Outlook

Despite increasing macroeconomic and industry uncertainties the Company firmly

believes that the evolving healthcare demands and technological innovations will

sustain the development of our industry

Continue to develop our end-to-end fully integrated and multiple modalities-capable

services platform with global footprints to further support our customers in improving

the efficiency and flexibility of their pharmaceutical R&D and manufacturing needs

Expect to deliver 10~15% revenue growth in 2025

Disclaimer: These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about

the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ 12

materially from these forward-looking statementsTHANK YOU